Compare iShares MSCI South Korea ETF (EWY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Mesoblast Limited — how do they compare? iShares MSCI South Korea ETF trades at $178.4 (market cap $26.25B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: iShares MSCI South Korea ETF is far larger — about 15× Mesoblast Limited's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Mesoblast Limited for 14 Days on average.
| EWY | MESO | |
|---|---|---|
Market Cap | $26.25B | $1.75B |
Volume | 19,056,075 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $20.96 |
52-Week Low | $80.72 | $13.19 |
Typical Hold Time | 46 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $183.72, down 1.44% amid mixed technical signals and KOSPI volatility driven by semiconductor sector sensitivity. The ETF shows neutral momentum with bullish moving averages but faces resistance near $185. Recent news highlights South Korea's strong 2026 market performance and AI-driven semiconductor demand, though concerns persist about high oil prices and rising US yields impacting tech valuations.
Outlook remains cautiously optimistic given EWY's heavy concentration in Samsung and SK hynix, which benefit from AI memory cycle strength. Key risks include reliance on two stocks, geopolitical tensions, and macroeconomic pressures. The ETF offers exposure to South Korea's tech-led growth but requires monitoring of memory cycle trends and foreign investor flows.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
